To include your compound in the COVID-19 Resource Center, submit it here.

FDA reviewing safety of GnRH agonists

FDA is reviewing the safety of gonadotropin-releasing hormone (GnRH) agonists after data from published studies showed

Read the full 161 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE